BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28972041)

  • 1. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.
    Tobin NP; Lundberg A; Lindström LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Fernö M; Czene K; Perou CM; Bergh J; Hatschek T;
    Clin Cancer Res; 2017 Dec; 23(23):7225-7231. PubMed ID: 28972041
    [No Abstract]   [Full Text] [Related]  

  • 2. A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR
    Zhang Y; Schroeder BE; Jerevall PL; Ly A; Nolan H; Schnabel CA; Sgroi DC
    Clin Cancer Res; 2017 Dec; 23(23):7217-7224. PubMed ID: 28939745
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes.
    Liu R; Zhang W; Liu ZQ; Zhou HH
    Oncotarget; 2016 Apr; 7(16):21686-98. PubMed ID: 26934123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
    Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindström LS; Tobin NP
    Breast Cancer Res; 2024 Mar; 26(1):38. PubMed ID: 38454481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and multivariate analysis of prognostic factors in recurrent laryngeal carcinoma].
    Chen YF; Chen FJ; Yang AK; Zeng ZY; Song M; Li QL
    Ai Zheng; 2004 May; 23(5):584-8. PubMed ID: 15142460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research-based PAM50 signature and long-term breast cancer survival.
    Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
    Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
    Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
    Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
    [No Abstract]   [Full Text] [Related]  

  • 11. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
    Kimbung S; Johansson I; Danielsson A; Veerla S; Egyhazi Brage S; Frostvik Stolt M; Skoog L; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Loman N; Malmström PO; Söderberg M; Walz TM; Fernö M; Hatschek T; Hedenfalk I;
    Clin Cancer Res; 2016 Jan; 22(1):146-57. PubMed ID: 26276891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
    Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.
    Tobin NP; Wennmalm K; Lindström LS; Foukakis T; He L; Genové G; Östman A; Landberg G; Betsholtz C; Bergh J
    Clin Cancer Res; 2016 May; 22(10):2417-26. PubMed ID: 26769751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
    Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
    Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
    Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
    J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
    Sgroi DC; Chapman JA; Badovinac-Crnjevic T; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Shepherd LE; Goss PE; Pollak M
    Breast Cancer Res; 2016 Jan; 18(1):1. PubMed ID: 26728744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.
    Tobin NP; Harrell JC; Lövrot J; Egyhazi Brage S; Frostvik Stolt M; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Walz T; Fernö M; Perou CM; Bergh J; Hatschek T; Lindström LS;
    Ann Oncol; 2015 Jan; 26(1):81-88. PubMed ID: 25361981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.